Is MBX Biosciences, Inc. (MBX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 19.1% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 19.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.1% / 33% | 97.6% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 19.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.1% / 33% | 97.6% / 33% | 0.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -27.8% | |
| Return on Assets (ROA) | -18.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$80M |
| Free Cash Flow | -$82M |
| Total Debt | $596,000 |
| Debt-to-Equity | 0.2 |
| Current Ratio | 24.6 |
| Total Assets | $385M |
Price & Trading
| Last Close | $28.29 |
| 50-Day MA | $34.37 |
| 200-Day MA | $22.83 |
| Avg Volume | 637K |
|
52-Week Range
$4.81
| |
About MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MBX Biosciences, Inc. (MBX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MBX Biosciences, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MBX Biosciences, Inc.'s debt ratio?
MBX Biosciences, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.1%.
What are MBX Biosciences, Inc.'s key financial metrics?
MBX Biosciences, Inc. has a market capitalization of $1.4B. Return on equity stands at -27.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.